
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
SkinHealth Systems is poised to continue its strong financial performance and growth as it expands its global presence in the medical aesthetics market through its highly effective and innovative brands, including Hydrafacial and SkinStylus. With a solid balance sheet and increasing profitability, the company is well-positioned to address any long-term debt maturities and invest in new product development to drive future growth. However, potential risks include ongoing challenges in converting profitability into free cash flow and intensifying competition in the aesthetics landscape.
Bears say
SkinHealth Systems is facing a number of fundamental challenges including a decline in revenue due to capital constraints, weaker utilization of consumables, and a lower active install base. In addition, the company's significant convertible debt maturity in 2028 poses a long-term balance-sheet overhang. While the company is taking measures to address these issues, there are still risks of lower consumer demand and market share loss, as well as the potential for patent expiration and challenges in maintaining its brand reputation. These challenges, along with a slower-than-expected recovery in sales, lead to a negative outlook on the stock.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares